ESR1 and endometrial cancer: So far, our study is the first to provide data about the potential use of 18F-FDG PET/CT in the prediction of ER/PR status in endometrial cancer, as well as to show that 18F-FDG PET/CT has great effects on determining optimal treatment methods by predicting the response to progestogen treatment in endometrial cancers.